Incyte Corp. (INCY)
Nasdaq: INCY · Services-Commercial Physical & Biological Research · Wilmington, DE · filing with the SEC since 1994
Grade7.5
◀ Past 7.7● Present 7.1▶ Future 7.8
Who owns Incyte Corp.
As filed with the SECHolders of 5% or more
4
Julian C. Baker holds 15.6% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D/A filed May 11, 2026 says.
Directors and officers
27
report now, of 45 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Julian C. Baker
SCHEDULE 13D/A · filed May 11, 2026 · Common Stock, $0.001 par value per share · 15.7% in Feb 10, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 17, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
Dodge & Cox
SCHEDULE 13G/A · filed May 14, 2026 · Common Stock
State Street Corporation
SCHEDULE 13G · filed Nov 10, 2025 · COMMON STOCK · reported falling below 5%
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What INCY reports owning in othersstakes of 5% or more, and other ties
Prelude Therapeutics Incorporated PRLD
SCHEDULE 13G · filed Nov 7, 2025 · Common Stock, par value $0.0001 per share
Other ties the annual report names
Investment in Prelude
An investee · investee · invested in, named in the 10-K filed Feb 10, 2026
Investment in Syndax
An investee · investee · invested in, named in the 10-K filed Feb 10, 2026
Merus
An investee · investee · invested in, named in the 10-K filed Feb 10, 2026
MorphoSys AG
An investee · investee · invested in, named in the 10-K filed Feb 10, 2026
Escient Pharmaceuticals
A company bought · asset acquisition · owns, named in the 10-K filed Feb 10, 2026
29 subsidiaries in 19 countries, from the list filed with the 10-K filed Feb 10, 2026.
Insider tradesForm 4
49sales
0purchases
49sales on a scheduled plan
8people selling
$66.1Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 10, 2025 to Nov 10, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 10, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window9 of 45 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Stein Steven H | CMO & Head of Late-Stage Dev. | 10 | $35.8M | 10 | 0 | $0 |
| Hoppenot Herve | Special Advisor to the CEO | 1 | $19.8M | 1 | 0 | $0 |
| Cagnoni Pablo J | President, Global Head of R&D | 10 | $14.4M | 10 | 0 | $0 |
| Mayes Patrick A | EVP & Chief Scientific Officer | 15 | $6.6M | 15 | 0 | $0 |
| Morrissey Michael James | EVP, Head of Tech. Operations | 3 | $5.7M | 3 | 0 | $0 |
| Clancy Paul J | director | 1 | $1.4M | 1 | 0 | $0 |
| Issa Mohamed Khairie | EVP, Head of U.S. Commercial | 2 | $1.3M | 2 | 0 | $0 |
| Tray Thomas | Principal Accounting Officer | 7 | $1.0M | 7 | 0 | $0 |
| Denton Sheila A. | EVP & General Counsel | 1 | $0 | 1 | 0 | $0 |